British Columbia’s influential psychedelics company, Optimi Health Corp (CNSX: OPTI) (OTCMKTS: OPTHF) (FRA: 8BN), has produced a batch of over 4,000 MDMA capsules to support international clinical research and people who could benefit from their consumption. This amount is unprecedented.
These pills and additional capsules manufactured in the coming weeks will be sent to Israel for a Phase II clinical trial investigating the drug’s impact on PTSD. Additionally, they will be used to treat mental health conditions among Canadian and Australian patients who have obtained approval to receive them.
“What we find most rewarding is that a portion of this latest batch will be directly used to treat patients in 2025 in Australia,” Optimi’s new chief executive, Dane Stevens, said in a release, “where a growing number of authorized doctors are prescribing Optimi’s MDMA for PTSD under the Authorized Prescriber Scheme.”
This Australian regulatory framework came into effect in July of 2023. The nation’s renowned charity, Mind Medicine Australia, was instrumental in pushing for rescheduling of MDMA and psilocybin in the country, and was ultimately successful with its campaign earlier that year.
Optimi is known to have a significant supply agreement with this organization. The company received an import permit to send the charity capsules of the compounds in May. Mind Medicine Australia’s Patient Support Fund helped provide these unorthodox therapeutic drugs to over 70 Australian citizens in clinical settings throughout 2024.
Read more: Edmonton’s new psychedelic therapy clinic helps residents soothe the winter blues
Read more: MindBio Therapeutics uses AI speech analysis to see if you’ve taken its LSD drug
Optimi closes 2nd tranche of private placement
A sum of C$395,000 went into the company’s pockets this week to help fund its activities. The investor received 1.3 million shares for this final chunk of funding. They have provided Optimi with a total of C$934,000.
This sum builds on a C$1.5-million-dollar private placement received in mid-2024.
Optimi Health is based in the small BC town of Princeton, where it has two facilities spanning 20,000 square feet. Health Canada has licensed the drug developer for its initiatives.
Last spring, Optimi initiated a psilocybin mushroom research partnership with Kwantlen Polytechnic University. These studies are ongoing.
“This work will be exceptionally valuable for establishing a baseline of the genetic identity of the various species of psilocybin-containing mushrooms being cultivated at Optimi now and in the future,” mycology and cultivation lead, Scott Marshall, said in a statement on Apr. 23.
rowan@mugglehead.com
